Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2016 1
2017 1
2020 1
2021 3
2022 7
2023 2
2024 2
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean munasinghe p (21 results)?
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Guglielmetti L, et al. N Engl J Med. 2025 Jan 30;392(5):468-482. doi: 10.1056/NEJMoa2400327. N Engl J Med. 2025. PMID: 39879593 Free PMC article. Clinical Trial.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Among authors: rupasinghe p. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.
Rupasinghe P, Ismail N, Mulders W, Warren RM, Joseph L, Ngcamu D, Gwala T, Omar SV, Vereecken J, de Jong BC, Rigouts L, Borroni E, Cirillo DM, Schön T, Miotto P, Köser CU. Rupasinghe P, et al. Antimicrob Agents Chemother. 2025 Nov 5;69(11):e0111325. doi: 10.1128/aac.01113-25. Epub 2025 Sep 22. Antimicrob Agents Chemother. 2025. PMID: 40980917 Free PMC article.
Reduced critical concentration might not have improved MGIT-based DST's sensitivity to rifampicin.
Rupasinghe P, Ashraf A, Barreda N, Parveen S, Zubair M, Calderon R, Asif S, Hirani N, Chingisova L, Bulane A, Hang PT, Ha DT, Ardizzoni E, Kursheed N, De Rijk WB, Rigouts L, Guglielmetti L, Mitnick C, de Jong BC. Rupasinghe P, et al. Antimicrob Agents Chemother. 2024 May 2;68(5):e0170123. doi: 10.1128/aac.01701-23. Epub 2024 Mar 27. Antimicrob Agents Chemother. 2024. PMID: 38534101 Free PMC article. No abstract available.
Balancing access to BPaLM regimens and risk of resistance.
Van Rie A, Walker T, de Jong B, Rupasinghe P, Rivière E, Dartois V, Sonnenkalb L, Machado D, Gagneux S, Supply P, Dreyer V, Niemann S, Goig G, Meehan C, Tagliani E, Cirillo DM. Van Rie A, et al. Among authors: rupasinghe p. Lancet Infect Dis. 2022 Oct;22(10):1411-1412. doi: 10.1016/S1473-3099(22)00543-6. Epub 2022 Aug 22. Lancet Infect Dis. 2022. PMID: 36007529 No abstract available.
22 results